好中球減少症治療の世界市場2020-2026:流通経路別(小売薬局、病院薬局、オンライン薬局)、治療別、地域別

◆英語タイトル:Global Neutropenia Treatment Market By Distribution channel (Retail pharmacies, Hospital pharmacies and Online pharmacies), By Treatment (Colony-stimulating factor, Antibiotics, Antifungals and Antivirals), By Region, Industry Analysis and Forecast, 2020 - 2026
◆商品コード:KBV20OCT048
◆発行会社(リサーチ会社):KBV Research
◆発行日:2020年6月30日
◆ページ数:155
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ、カナダ、メキシコ、ロシア、ドイツ、イギリス、フランス、スペイン、イタリア、中国、日本、インド、韓国、シンガポール、マレーシア、ブラジル、アルゼンチン、アラブ首長国連邦、サウジアラビア、南アフリカ、ナイジェリア
◆販売価格オプション(消費税別)
Single User(1名様利用)USD3,600 ⇒換算¥388,800見積依頼/購入/質問フォーム
Global License(法人利用)USD6,048 ⇒換算¥653,184見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKBV Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
KBV Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、好中球減少症治療の世界市場について、市場範囲・調査手法、市場概要、流通経路別(小売薬局、病院薬局、オンライン薬局)分析、治療別分析、地域別分析、企業概要などを総合的、多面的に調査・分析しました。
・市場範囲・調査手法
・市場概要
・好中球減少症治療の世界市場規模:流通経路別(小売薬局、病院薬局、オンライン薬局)
・好中球減少症治療の世界市場規模:治療別
・好中球減少症治療の世界市場規模:地域別
・企業概要
【レポートの概要】

The Global Neutropenia Treatment Market size is expected to reach $18.9 billion by 2026, rising at a market growth of 6.5% CAGR during the forecast period. Neutropenia is an abnormal condition characterized by a critically low level of circulating neutrophils, a type of WBC found in the blood. These cells make up the majority of circulating lymphocytes and help protect the body from infections caused by bacteria, viruses, and other pathogenic organisms. A decrease in the amount of neutrophil in the blood allows a patient to be vulnerable to infection and can also prove fatal. The condition, therefore, requires immediate prophylaxis.

Novel treatments combined with growing cases of chemotherapy-induced neutropenia are one of the primary drivers of market growth. In addition, the novel drug delivery strategy also increases patient convenience, leading to greater adherence to the patient and thereby stimulates the growth of the market. Moreover, since cancer is a known cause of developing neutropenia, increasing cases of chemotherapy for cancer treatment will be a growth driver for the neutropenia treatment market.

One of the new developments to gain momentum in the global neutropenia treatment market is the introduction of small molecules. The development of Plinabulin, a small molecule developed by BeyondSpring Pharmaceuticals with immune-boosting effects, is expected to revolutionize the therapeutic regimen for neutropenia. In addition to the immune-boosting effects, the Phase II studies have revealed much more beneficial anti-cancer effects of this molecule. Currently, there is a high demand for cost-effective drugs for treatment in the neutropenia treatment market. As a result, vendors are focused on the production of small molecules with lower processing costs than biologics.

Based on Distribution channel, the market is segmented into Retail pharmacies, Hospital pharmacies and Online pharmacies. Based on Treatment, the market is segmented into Colony-stimulating factor, Antibiotics, Antifungals and Antivirals. Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Amgen, Inc., Novartis AG, Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., BeyondSpring, Inc., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd. (Kirin Company), Mylan N.V., Cellerant Therapeutics, Inc., and Partner Therapeutics, Inc.

Strategies deployed in Neutropenia Treatment Market

Jun-2020: Pfizer got FDA approval for NYVEPRIA (pegfilgrastim-apgf), a biosimilar to Neulasta (pegfilgrastim). NYVEPRIA is used for decreasing the incidence of infection, as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Apr-2020: Mylan collaborated with Biocon, a biopharmaceutical company. Together, the companies launched Fulphila, a biosimilar to Neulasta (pegfilgrastim) in Australia and Canada for cancer patients. Fulphila is used for the treatment of cancer patients following chemotherapy, to decrease the duration of severe neutropenia and reduce the incidence of infections, as manifested by febrile neutropenia. The companies got FDA approval for Fulphila in June, 2018.
Nov-2019: Sandoz, a Novartis division got FDA approval for Ziextenzo (pegfilgrastim-bmez). Ziextenzo has been used to decrease the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy.
Nov-2019: Teva Pharmaceuticals teamed up with Celltrion, Inc., a biopharmaceutical company. Together, the companies announced the launch of TRUXIMA (rituximab-abbs) injection. TRUXIMA is currently indicated for the treatment of adult patients with non-Hodgkin’s Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL).
Jul-2019: Pfizer acquired Array BioPharma Inc., a pharmaceutical company. The acquisition strengthened Pfizer’s innovative biopharmaceutical business and category leadership in Oncology expected acceleration of Pfizer’s long-term growth trajectory through new medicines.
Nov-2018: Partner Therapeutics announced that FDA has granted orphan drug designation to Leukine (sargramostim), a yeast-derived recombinant human granulocyte-macrophage colony stimulating factor (rhu-GM-CSF). This drug is used for the treatment of pulmonary alveolar proteinosis (PAP). Leukine works by stimulating the production of white blood cells including neutrophils, monocytes/macrophages and myeloid-derived dendritic cell and promoting their ability to function.
Jul-2018: Cellerant Therapeutics announced that FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation for romyelocel-L (human myeloid progenitor cells) for the prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy.
Jul-2018: Pfizer announced that it received FDA approval for NIVESTYM (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). This drug expanded the access to critical treatment options for patients with neutropenia.
Feb-2018: Partner Therapeutics signed an agreement with Sanofi. Following the agreement, the former company acquired the global rights for developing, manufacturing, and commercializing Leukine (sargramostim). Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infection.

Scope of the Study
Market Segmentation:

By Distribution Channel
• Retail pharmacies
• Hospital pharmacies and
• Online pharmacies

By Treatment
• Colony-stimulating factor
• Antibiotics
• Antifungals and
• Antivirals

By Geography
• North America
o US
o Canada
o Mexico
o Rest of North America
• Europe
o Germany
o UK
o France
o Russia
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o Japan
o India
o South Korea
o Singapore
o Malaysia
o Rest of Asia Pacific
• LAMEA
o Brazil
o Argentina
o UAE
o Saudi Arabia
o South Africa
o Nigeria
o Rest of LAMEA

Companies Profiled
• Amgen, Inc.
• Novartis AG
• Pfizer, Inc.
• Teva Pharmaceuticals Industries Ltd.
• BeyondSpring, Inc.
• Spectrum Pharmaceuticals, Inc.
• Kyowa Kirin Co., Ltd. (Kirin Company)
• Mylan N.V.
• Cellerant Therapeutics, Inc.
• Partner Therapeutics, Inc.

Unique Offerings from KBV Research
• Exhaustive coverage
• Highest number of market tables and figures
• Subscription based model available
• Guaranteed best price
• Assured post sales research support with 10% customization free

【レポートの目次】

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Neutropenia Treatment Market, by Distribution Channel
1.4.2 Global Neutropenia Treatment Market, by Treatment
1.4.3 Global Neutropenia Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Neutropenia Treatment Market by Distribution channel
3.1 Global Retail pharmacies Market by Region
3.2 Global Hospital pharmacies Market by Region
3.3 Global Online pharmacies Market by Region
Chapter 4. Global Neutropenia Treatment Market by Treatment
4.1 Global Colony-stimulating factor Market by Region
4.2 Global Antibiotics Market by Region
4.3 Global Antifungals Market by Region
4.4 Global Antivirals Market by Region
Chapter 5. Global Neutropenia Treatment Market by Region
5.1 North America Neutropenia Treatment Market
5.1.1 North America Neutropenia Treatment Market by Distribution channel
5.1.1.1 North America Retail pharmacies Market by Country
5.1.1.2 North America Hospital pharmacies Market by Country
5.1.1.3 North America Online pharmacies Market by Country
5.1.2 North America Neutropenia Treatment Market by Treatment
5.1.2.1 North America Colony-stimulating factor Market by Country
5.1.2.2 North America Antibiotics Market by Country
5.1.2.3 North America Antifungals Market by Country
5.1.2.4 North America Antivirals Market by Country
5.1.3 North America Neutropenia Treatment Market by Country
5.1.3.1 US Neutropenia Treatment Market
5.1.3.1.1 US Neutropenia Treatment Market by Distribution channel
5.1.3.1.2 US Neutropenia Treatment Market by Treatment
5.1.3.2 Canada Neutropenia Treatment Market
5.1.3.2.1 Canada Neutropenia Treatment Market by Distribution channel
5.1.3.2.2 Canada Neutropenia Treatment Market by Treatment
5.1.3.3 Mexico Neutropenia Treatment Market
5.1.3.3.1 Mexico Neutropenia Treatment Market by Distribution channel
5.1.3.3.2 Mexico Neutropenia Treatment Market by Treatment
5.1.3.4 Rest of North America Neutropenia Treatment Market
5.1.3.4.1 Rest of North America Neutropenia Treatment Market by Distribution channel
5.1.3.4.2 Rest of North America Neutropenia Treatment Market by Treatment
5.2 Europe Neutropenia Treatment Market
5.2.1 Europe Neutropenia Treatment Market by Distribution channel
5.2.1.1 Europe Retail pharmacies Market by Country
5.2.1.2 Europe Hospital pharmacies Market by Country
5.2.1.3 Europe Online pharmacies Market by Country
5.2.2 Europe Neutropenia Treatment Market by Treatment
5.2.2.1 Europe Colony-stimulating factor Market by Country
5.2.2.2 Europe Antibiotics Market by Country
5.2.2.3 Europe Antifungals Market by Country
5.2.2.4 Europe Antivirals Market by Country
5.2.3 Europe Neutropenia Treatment Market by Country
5.2.3.1 Germany Neutropenia Treatment Market
5.2.3.1.1 Germany Neutropenia Treatment Market by Distribution channel
5.2.3.1.2 Germany Neutropenia Treatment Market by Treatment
5.2.3.2 UK Neutropenia Treatment Market
5.2.3.2.1 UK Neutropenia Treatment Market by Distribution channel
5.2.3.2.2 UK Neutropenia Treatment Market by Treatment
5.2.3.3 France Neutropenia Treatment Market
5.2.3.3.1 France Neutropenia Treatment Market by Distribution channel
5.2.3.3.2 France Neutropenia Treatment Market by Treatment
5.2.3.4 Russia Neutropenia Treatment Market
5.2.3.4.1 Russia Neutropenia Treatment Market by Distribution channel
5.2.3.4.2 Russia Neutropenia Treatment Market by Treatment
5.2.3.5 Spain Neutropenia Treatment Market
5.2.3.5.1 Spain Neutropenia Treatment Market by Distribution channel
5.2.3.5.2 Spain Neutropenia Treatment Market by Treatment
5.2.3.6 Italy Neutropenia Treatment Market
5.2.3.6.1 Italy Neutropenia Treatment Market by Distribution channel
5.2.3.6.2 Italy Neutropenia Treatment Market by Treatment
5.2.3.7 Rest of Europe Neutropenia Treatment Market
5.2.3.7.1 Rest of Europe Neutropenia Treatment Market by Distribution channel
5.2.3.7.2 Rest of Europe Neutropenia Treatment Market by Treatment
5.3 Asia Pacific Neutropenia Treatment Market
5.3.1 Asia Pacific Neutropenia Treatment Market by Distribution channel
5.3.1.1 Asia Pacific Retail pharmacies Market by Country
5.3.1.2 Asia Pacific Hospital pharmacies Market by Country
5.3.1.3 Asia Pacific Online pharmacies Market by Country
5.3.2 Asia Pacific Neutropenia Treatment Market by Treatment
5.3.2.1 Asia Pacific Colony-stimulating factor Market by Country
5.3.2.2 Asia Pacific Antibiotics Market by Country
5.3.2.3 Asia Pacific Antifungals Market by Country
5.3.2.4 Asia Pacific Antivirals Market by Country
5.3.3 Asia Pacific Neutropenia Treatment Market by Country
5.3.3.1 China Neutropenia Treatment Market
5.3.3.1.1 China Neutropenia Treatment Market by Distribution channel
5.3.3.1.2 China Neutropenia Treatment Market by Treatment
5.3.3.2 Japan Neutropenia Treatment Market
5.3.3.2.1 Japan Neutropenia Treatment Market by Distribution channel
5.3.3.2.2 Japan Neutropenia Treatment Market by Treatment
5.3.3.3 India Neutropenia Treatment Market
5.3.3.3.1 India Neutropenia Treatment Market by Distribution channel
5.3.3.3.2 India Neutropenia Treatment Market by Treatment
5.3.3.4 South Korea Neutropenia Treatment Market
5.3.3.4.1 South Korea Neutropenia Treatment Market by Distribution channel
5.3.3.4.2 South Korea Neutropenia Treatment Market by Treatment
5.3.3.5 Singapore Neutropenia Treatment Market
5.3.3.5.1 Singapore Neutropenia Treatment Market by Distribution channel
5.3.3.5.2 Singapore Neutropenia Treatment Market by Treatment
5.3.3.6 Malaysia Neutropenia Treatment Market
5.3.3.6.1 Malaysia Neutropenia Treatment Market by Distribution channel
5.3.3.6.2 Malaysia Neutropenia Treatment Market by Treatment
5.3.3.7 Rest of Asia Pacific Neutropenia Treatment Market
5.3.3.7.1 Rest of Asia Pacific Neutropenia Treatment Market by Distribution channel
5.3.3.7.2 Rest of Asia Pacific Neutropenia Treatment Market by Treatment
5.4 LAMEA Neutropenia Treatment Market
5.4.1 LAMEA Neutropenia Treatment Market by Distribution channel
5.4.1.1 LAMEA Retail pharmacies Market by Country
5.4.1.2 LAMEA Hospital pharmacies Market by Country
5.4.1.3 LAMEA Online pharmacies Market by Country
5.4.2 LAMEA Neutropenia Treatment Market by Treatment
5.4.2.1 LAMEA Colony-stimulating factor Market by Country
5.4.2.2 LAMEA Antibiotics Market by Country
5.4.2.3 LAMEA Antifungals Market by Country
5.4.2.4 LAMEA Antivirals Market by Country
5.4.3 LAMEA Neutropenia Treatment Market by Country
5.4.3.1 Brazil Neutropenia Treatment Market
5.4.3.1.1 Brazil Neutropenia Treatment Market by Distribution channel
5.4.3.1.2 Brazil Neutropenia Treatment Market by Treatment
5.4.3.2 Argentina Neutropenia Treatment Market
5.4.3.2.1 Argentina Neutropenia Treatment Market by Distribution channel
5.4.3.2.2 Argentina Neutropenia Treatment Market by Treatment
5.4.3.3 UAE Neutropenia Treatment Market
5.4.3.3.1 UAE Neutropenia Treatment Market by Distribution channel
5.4.3.3.2 UAE Neutropenia Treatment Market by Treatment
5.4.3.4 Saudi Arabia Neutropenia Treatment Market
5.4.3.4.1 Saudi Arabia Neutropenia Treatment Market by Distribution channel
5.4.3.4.2 Saudi Arabia Neutropenia Treatment Market by Treatment
5.4.3.5 South Africa Neutropenia Treatment Market
5.4.3.5.1 South Africa Neutropenia Treatment Market by Distribution channel
5.4.3.5.2 South Africa Neutropenia Treatment Market by Treatment
5.4.3.6 Nigeria Neutropenia Treatment Market
5.4.3.6.1 Nigeria Neutropenia Treatment Market by Distribution channel
5.4.3.6.2 Nigeria Neutropenia Treatment Market by Treatment
5.4.3.7 Rest of LAMEA Neutropenia Treatment Market
5.4.3.7.1 Rest of LAMEA Neutropenia Treatment Market by Distribution channel
5.4.3.7.2 Rest of LAMEA Neutropenia Treatment Market by Treatment
Chapter 6. Company Profiles
6.1 Amgen, Inc.
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Research & Development Expense
6.2 Novartis AG
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Segmental and Regional Analysis
6.2.4 Recent strategies and developments:
6.2.4.1 Approvals:
6.3 Pfizer, Inc.
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Segmental and Regional Analysis
6.3.4 Recent strategies and developments:
6.3.4.1 Approvals:
6.3.4.2 Acquisition and Mergers:
6.4 Teva Pharmaceutical Industries Ltd.
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expenses
6.4.5 Recent strategies and developments:
6.4.5.1 Partnerships, Collaborations, and Agreements:
6.5 BeyondSpring, Inc.
6.5.1 Company Overview
6.6 Spectrum Pharmaceuticals, Inc.
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Research & Development Expenses
6.7 Kyowa Kirin Co., Ltd. (Kirin Company)
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expense
6.8 Mylan N.V.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Regional Analysis
6.8.4 Research & Development Expense
6.8.5 Recent strategies and developments:
6.8.5.1 Partnerships, Collaborations, and Agreements:
6.9 Cellerant Therapeuticsc, Inc.
6.9.1 Company Overview
6.9.2 Recent strategies and developments:
6.9.2.1 Approvals:
6.1 Partner Therapeutics, Inc.
6.10.1 Company overview
6.10.2 Recent strategies and developments:
6.10.2.1 Partnerships, Collaborations, and Agreements:
6.10.2.2 Approvals:



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[好中球減少症治療の世界市場2020-2026:流通経路別(小売薬局、病院薬局、オンライン薬局)、治療別、地域別]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆